Anavex Life Sciences Corp (AVXL)

[Investor2014]

That was quite a few years ago!

When you know what we did and why we did it, you will understand

At the time of that quote, Missling had no clue how well or not A2-73 would perform clinically.

Just stating 'All end points met' in the P2b/3 trial doesn't tell us anything about how well A2-73 performs in the clinic (that missing n thing associated with the Odds Ratio thresholds). Biogen/Eisai released lecanamab data that met all endpoints by the book, but I think we can all agree that didn't mean amazing clinically meaningful outcomes.

We still need to fully appreciate how well A2-73 actually performed in the clinic. We are again waiting on another peer reviewed paper to more fully understand the P2b/3 results, but with fewer limitations, than we now understand the very small open label P2a results.